hackint0sh/New-Dataset huggingface dataset:
Research questions Is there any improvement in airway remodeling? Are there any biomarkers to predict response to benralizumab treatment in severe eosinophilic asthmatic patients? conditions: Asthma; Eosinophilic conditions: Airway Remodeling studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Benralizumab (30mg) administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: Benralizumab 30 mg/ml measure: Change in sub-basement membrane thickness measure: Change in airway smooth muscle area measure: Change in airway smooth muscle layer thickness measure: Change in submucosal eosinophil number measure: Change in epithelial integrity measure: Change in collagen thickness measure: Change of cytokine and protein levels measure: Change in exacerbation rate measure: Change in blood eosinophil levels measure: dentification of clinical characteristics of response, change in Forced Expiratory Volume (FEV1) sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Pulmonary Clinic, Aristotle University of Thessaloniki, George Papanikolaou Hospital status: RECRUITING city: Thessaloniki zip: 57010 country: Greece name: Kalliopi Domvri, Dr role: CONTACT phone: 00302313307258 email: kdomvrid@auth.gr name: Konstantinos Porpodis, Prof role: CONTACT phone: 00302313307179 email: kporpodis@yahoo.gr lat: 40.64361 lon: 22.93086 hasResults: False
nctId: NCT06288503 id: HRF2023 briefTitle: Hydrolysed Rice Formula Study overallStatus: RECRUITING date: 2024-02-01 date: 2027-07 date: 2027-07 date: 2024-03-01 date: 2024-03-01 name: Nutricia UK Ltd class: INDUSTRY briefSummary: This non-inferiority study aims to determine whether a hydrolysed rice protein formula is as effective as a cow's milk protein based extensively hydrolysed formula using a double-blind, randomised-controlled design over a 28-day intervention period followed by a 2-month follow-up period in infants 0-13 months of age presenting with symptoms/clinical history suggestive of cow's milk allergy. The primary outcome is growth, and secondary outcomes are gastrointestinal tolerance, and differences in intake, allergic symptoms, parental QOL, acceptability, dietary intake, and safety. conditions: Cow's Milk Protein Allergy studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 86 type: ESTIMATED name: Hydrolysed Rice Protein Formula name: Cow's Milk Based Extensively Hydrolysed Formula measure: Growth measure: Gastrointestinal Tolerance measure: Stool frequency and consistency measure: Study Product Intake measure: Patient Orientated Scoring Atopic Dermatitis Symptoms (PO-SCORAD) measure: Patient Reported Atopic Symptoms measure: Cow's Milk Related Symptom Score measure: Food Allergy Quality of Life-Parental Burden (FAQL-PB) measure: Acceptability of the Study Formula measure: Nutrient Intake (Energy, Protein, Micronutrients) measure: Dietetic Goal measure: Overall Safety sex: ALL minimumAge: 0 Months maximumAge: 13 Months stdAges: CHILD facility: Gloucestershire Royal NHS Trust status: RECRUITING city: Gloucester state: Gloucestershire zip: GL1 3NN country: United Kingdom name: Victoria Bittle role: CONTACT phone: 0300 422 5506 email: v.bittle@nhs.net lat: 51.86568 lon: -2.2431 facility: Bristol Royal Hospital for Children status: RECRUITING city: Bristol state: Somerset zip: BS16 1TA country: United Kingdom name: Sarah Trace role: CONTACT phone: 0117 3428802 email: sarah.trace@uhbw.nhs.uk lat: 51.45523 lon: -2.59665 hasResults: False
nctId: NCT06288490 id: AMCS-009 briefTitle: A Single Arm Study Comparing ACC Supplement to CCS in Management of Hypoparathyroidism acronym: AMCS009 overallStatus: TERMINATED date: 2013-04 date: 2014-06 date: 2014-06-25 date: 2024-03-01 date: 2024-03-01 name: Amorphical Ltd. class: INDUSTRY briefSummary: Primary objective:
The study is designed to be conducted with extra precaution in order to avoid disturbing the fragile balance between CA levels in serum and calcium levels urine. The crossover design of phase II of the study allows a more accurate and reliable comparison of results attributable to the specific treatment within the same individual. In addition, the subjects will continue consuming all their routine medication throughout the trial. The subjects in the control arm will consume their routine calcium supplement doses thus, will be treated with a standard of care. conditions: Hypoparathyroidism studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Proof of concept: treatment with smaller doses of elemental calcium from ACC compared to CCS can maintain target serum calcium (corrected for albumin) values (7.0-10.0 mg/dL) primaryPurpose: TREATMENT masking: NONE count: 10 type: ACTUAL name: amorphous calcium carbonate measure: Calcium (albumin-corrected) serum level - composite value based on multiple measurements measure: Urine calcium level - 24h urine collection measure: Phosphorous serum level - composite value based on multiple measurements measure: Urine calcium level - 24h urine collection measure: Urine calcium level - 24h urine collection measure: Assessment of symptoms and signs related with hypocalcemia - composite value based on multiple measurements measure: Urine creatinine level - 24h urine collection measure: Urine creatinine level - 24h urine collection measure: Urine creatinine level - 24h urine collection measure: Urine phosphorus level - 24h urine collection measure: Urine phosphorus level - 24h urine collection measure: Urine phosphorus level - 24h urine collection sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Rambam Health Care Campus city: Haifa zip: 31096 country: Israel lat: 32.81841 lon: 34.9885 hasResults: False
nctId: NCT06288477 id: 2023-2 briefTitle: Clinical and Radiographic Evaluation of Vital Pulpotomy Techniques in Primary Molars Using of Premixed Bioactive Bioceramic MTA (Neo-putty) as a Novel Pulpotomy Medication Versus Formocresol overallStatus: NOT_YET_RECRUITING date: 2024-03-20 date: 2024-05-01 date: 2025-02-01 date: 2024-03-01 date: 2024-03-18 name: October University for Modern Sciences and Arts class: OTHER briefSummary: Despite the benefit of formocresol, there are toxic effects allergic reactions and local soft and hard tissue necrosis have been reported when such formaldehyde compounds were used clinically, however, the adverse effect of the clinically used of this compound are not widely reported. It has been stated that it has a side effect on the permanent successor although it results as a successful technique for the treatment of the primary teeth conditions: Vital conditions: Pulpotomy conditions: Techniques studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 44 type: ESTIMATED name: A cotton pellet moistened with full-strength FC name: Neo-Putty measure: Clinical success sex: ALL minimumAge: 4 Years maximumAge: 9 Years stdAges: CHILD hasResults: False
nctId: NCT06288464 id: 315656 id: 22/WM/0222 type: OTHER domain: Health Research Authority briefTitle: Enteral Feeding of Fibre to Improve Microbiota overallStatus: RECRUITING date: 2023-01-09 date: 2025-12-01 date: 2025-12-01 date: 2024-03-01 date: 2024-03-01 name: Lancashire Teaching Hospitals NHS Foundation Trust class: OTHER name: Lancaster University briefSummary: Following surgical removal of diseased bowel, patients often require a temporary redirection of bowel contents to a stoma, to allow healing prior to re-joining of the remaining bowel at a later date. Some patients may experience complications, either during or after reversal surgery, and this may be due to changes in the 'friendly' bacteria that live in our bowels. Previous research shows that the distal section of bowel that is non-functioning undergoes tissue-wasting and the 'friendly' bacteria that help our digestion die. Data shows that patients that have a reduction in their microflora are more likely to experience side effects. This study investigates a method of replenishing the microflora prior to surgery. conditions: Bowel Dysfunction conditions: Colon Disease conditions: Ileum--Diseases studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: Cohort primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 15 type: ESTIMATED name: Soluble Fibre measure: Concentration of Microbiota measure: Concentration of Immune Cell Populations measure: Length of Stay measure: Rate of clinical complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Lancashire Teaching Hospitals NHS status: RECRUITING city: Preston state: Lancashire zip: PR2 9HT country: United Kingdom name: Kina Bennett role: CONTACT phone: (+44) 01772 522031 email: kina.bennett@lthtr.nhs.uk name: Research Access role: CONTACT email: research.access@lthtr.nhs.uk name: Arnab Bhowmick role: PRINCIPAL_INVESTIGATOR lat: 53.76282 lon: -2.70452 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-02-01 uploadDate: 2024-02-23T12:17 filename: Prot_000.pdf size: 250752 hasResults: False
nctId: NCT06288451 id: STUDY00018021 id: 1K23DK136930-01 type: NIH link: https://reporter.nih.gov/quickSearch/1K23DK136930-01 briefTitle: DePTH: De-emphasize PTH overallStatus: RECRUITING date: 2024-03-11 date: 2027-02-28 date: 2027-02-28 date: 2024-03-01 date: 2024-03-18 name: University of Washington class: OTHER name: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) briefSummary: The De-emphasize Parathyroid Hormone (DePTH) Study is a 12-month pragmatic, randomized, parallel-group, active comparator, open-label, blinded end-point study of 90 patients with incident or prevalent secondary hyperparathyroidism and kidney failure treated with in-center hemodialysis. It tests the hypothesis that low fixed-dose oral calcitriol (intervention) will have more favorable effects on a comprehensive panel of biomarkers that assesses mineral metabolism, bone turnover, and serum calcification propensity, compared with variably-dosed intravenous activated vitamin D titrated to PTH targets (usual care). conditions: Kidney Failure, Chronic conditions: Chronic Kidney Disease-Mineral and Bone Disorder studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 90 type: ESTIMATED name: Oral calcitriol with cinacalcet rescue name: IV activated vitamin D measure: Change in fibroblast growth factor-23 measure: Change in serum calcium measure: Change in serum phosphate measure: Change in serum bone-specific alkaline phosphatase measure: Change in serum parathyroid hormone measure: Change in T50 test of serum calcification propensity measure: Patient acceptability measure: Patient acceptability sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Washington status: RECRUITING city: Seattle state: Washington zip: 98104 country: United States name: Simon Hsu, MD, MS role: CONTACT phone: 206-540-5714 email: sihsu@uw.edu name: Ian H de Boer, MD, MS role: PRINCIPAL_INVESTIGATOR name: Simon Hsu, MD, MS role: PRINCIPAL_INVESTIGATOR lat: 47.60621 lon: -122.33207 hasResults: False
nctId: NCT06288425 id: SPACE-KIT briefTitle: Spatial Transcriptomics in Kidney Transplantation acronym: SPACE-KiT overallStatus: ENROLLING_BY_INVITATION date: 2024-04-03 date: 2030-01-01 date: 2035-01-01 date: 2024-03-01 date: 2024-04-24 name: Western Sydney Local Health District class: OTHER briefSummary: The study is an investigator-led, prospective, longitudinal, observational cohort study.
* Correlate of spatial and refined biopsy scoring features to clinically important outcomes conditions: Transplant Complication conditions: Kidney Injury studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 500 type: ESTIMATED name: Non interventional measure: Kidney biopsy features measure: Kidney biopsy transcriptomic signature measure: Kidney cell type composition measure: All cause graft loss measure: Death censored graft loss (DCGL) measure: Treatment resistant rejection measure: Delayed graft function (DGF) measure: Biopsy evidence of borderline rejection measure: Biopsy proven acute rejection measure: Chronic rejection measure: Interstitial fibrosis scores (IFTA) measure: BK virus associated nephropathy measure: Kidney function measure: Albuminuria measure: Surrogate end-points measure: Donor to recipient mismatches measure: Proteinomic signature sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Westmead Hospital city: Westmead state: New South Wales zip: 2145 country: Australia lat: -33.80383 lon: 150.98768 hasResults: False
nctId: NCT06288399 id: DAS-7688 id: U1111-1292-7248 type: OTHER domain: World Health Organization (WHO) briefTitle: Prevalence and Economic Burden of Obesity-related Comorbidities in the Gulf Region: A Retrospective, Observational Study overallStatus: ENROLLING_BY_INVITATION date: 2023-12-21 date: 2024-06-30 date: 2024-06-30 date: 2024-03-01 date: 2024-04-09 name: Novo Nordisk A/S class: INDUSTRY briefSummary: The aim of this study is to assess the annual prevalence of ORCs among adult people with obesity in the real-world clinical setting across the Gulf region. In addition, the study will describe the annual HCRU and associated costs of obesity and ORCs, describe the demographics and clinical characteristics of adult people with obesity, as well as estimate the annual incidence and point prevalence of the ORCs among adult people with obesity. conditions: Obesity studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 1322 type: ESTIMATED name: No treatment given measure: Proportion of Obesity Related Comorbidities (ORC, existing/newly diagnosed) among adult people with obesity (BMI above or equal to 30 kg/m2) over a period of 12 months across the Gulf region in primary and secondary hospitals as well as obesity clinics sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Farwaniya Hospital city: Farwaniya zip: 85000 country: Kuwait facility: Al-Adan Hospital city: Hadiya zip: 52700 country: Kuwait facility: Al-Amiri Hospital city: Kuwait City zip: 13001 country: Kuwait lat: 29.36972 lon: 47.97833 facility: Novo Nordisk Investigational Site city: Kuwait zip: 12030 country: Kuwait lat: 29.36972 lon: 47.97833 facility: National Diabetes and Endocrine Center city: Muscat zip: 113 country: Oman lat: 23.58413 lon: 58.40778 facility: Samail Polyclinic city: Samail zip: 620 country: Oman lat: 23.3 lon: 57.98333 facility: Hamad General Hospital city: Doha zip: 122104 country: Qatar lat: 25.28545 lon: 51.53096 facility: PHCC city: Doha zip: 122104 country: Qatar lat: 25.28545 lon: 51.53096 hasResults: False
nctId: NCT06288386 id: 2024-ATTACHMENTS briefTitle: Influence of Different Nanohybrid Flowable Composite Resin on Shear Bond Strength and Dimensional Changes of Invisalign Attachments After 6 Months of Brushing overallStatus: ENROLLING_BY_INVITATION date: 2024-03-04 date: 2025-02 date: 2025-02 date: 2024-03-01 date: 2024-03-15 name: University of Pavia class: OTHER briefSummary: The present study will be a single-center, split-mouth, randomized controlled clinical trial. Patients undergoing orthodontic treatment with Invisalign aligners will be enrolled after signing the informed consent. Two different flowable composite resins will be evaluated for the performing of attachments using a split-mouth design:
Type of brushing (with manual or electric toothbrush) and hand of brushing will be recorded. conditions: Malocclusion studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Split-mouth design primaryPurpose: BASIC_SCIENCE masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: GrandioSO Heavy Flow name: Filtek Z350XT Flowable measure: Changes in the volume of attachments measure: Attachments failure rate measure: Type of brushing measure: Change in questionnaire's answers measure: Hand of brushing sex: ALL minimumAge: 14 Years maximumAge: 70 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Unit of Orthodontics and Pediatric Dentistry - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Pediatrics - University of Pavia city: Pavia state: Lombardy zip: 27100 country: Italy lat: 45.19205 lon: 9.15917 hasResults: False
nctId: NCT06288373 id: NACI-CERV-003 briefTitle: Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2031-03-01 date: 2031-03-01 date: 2024-03-01 date: 2024-03-01 name: Tongji Hospital class: OTHER name: Southwest Hospital, China name: Women Hospital, School of Medicine, Zhejiang University name: Anhui Provincial Cancer Hospital name: Sichuan Cancer Hospital and Research Institute name: Qilu Hospital of Shandong University name: Beijing Friendship Hospital name: Tianjin Medical University General Hospital name: West China Second University Hospital name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University name: Xiangya Hospital of Central South University name: Gansu Provincial Maternal and Child Health Care Hospital name: Zhejiang Cancer Hospital name: Shengjing Hospital briefSummary: It is a prospective, open-label, randomized, controlled phase II/III clinical trial in which patients with PD-L1-positive FIGO stage IB3, IIA2 and IIB（tumors \>4 cm in diameter）will be enrolled and randomly divided into the neoadjuvant chemoimmunotherapy plus surgery group and the CCRT group. conditions: Cervical Cancer conditions: Locally Advanced Cervical Cancer conditions: Concurrent Chemoradiotherapy conditions: Neoadjuvant Chemoimmunotherapy studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 440 type: ESTIMATED name: Camrelizumab name: Cisplatin name: Nab paclitaxel name: Radical surgery name: external beam radiation therapy (EBRT) + brachytherapy name: Cisplatin measure: Progression-free survival, PFS measure: Objective Response Rate, ORR measure: Overall survival, OS measure: Proportion of patients undergoing radical surgery measure: Pathologic Complete Response measure: The surgical complication rate measure: Safety and toleraty measure: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) Physical Function Score measure: Change from Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Symptom Specific Scale for Cervical Cancer (EORTC QLQ-CX24) Score sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology city: Wuhan state: Hubei zip: 430030 country: China name: Kezhen Li role: CONTACT phone: 086-027-8362 email: tjkeke@126.com name: Jing Chen role: CONTACT phone: 086-027-8362 email: chenjing3223@126.com name: Kezhen Li role: PRINCIPAL_INVESTIGATOR name: Gang Chen role: PRINCIPAL_INVESTIGATOR lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06288360 id: NACI-CERV-002 briefTitle: Neoadjuvant Immunochemotherapy in PD-L1-negative LACC overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2025-12-31 date: 2030-12-12 date: 2024-03-01 date: 2024-03-01 name: Tongji Hospital class: OTHER name: Southwest Hospital, China name: Women Hospital, School of Medicine, Zhejiang University name: Anhui Provincial Cancer Hospital name: Sichuan Cancer Hospital and Research Institute name: Gansu Provincial Maternal and Child Health Care Hospital name: Beijing Friendship Hospital name: Tianjin Medical University General Hospital name: Xiangya Hospital of Central South University name: West China Second University Hospital name: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University name: Zhejiang Cancer Hospital name: Shengjing Hospital name: Qilu Hospital of Shandong University briefSummary: This is a multicenter, prospective, single-arm, phase 2 clinical trial designed to evaluate the therapeutic efficacy of the NACI (neoadjuvant chemotherapy plus Camrelizumab) for PD-L1-negative locally advanced cervical cancer. conditions: Cervical Cancer conditions: Locally Advanced Cervical Cancer conditions: PD-L1 Negative conditions: Neoadjuvant Chemoimmunotherapy studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Camrelizumab name: Paclitaxel-albumin name: Cisplatin name: radical surgery measure: Pathologic complete response measure: Surgical Complications measure: Objective response rate measure: Positive surgical margin rate measure: event-free survival measure: overall survival measure: adverse event sex: FEMALE minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology city: Wuhan state: Hubei zip: 430030 country: China name: Jing Chen role: CONTACT phone: 086-027-8362 email: chenjing3223@126.com name: Kezhen Li role: PRINCIPAL_INVESTIGATOR name: Gang Chen role: PRINCIPAL_INVESTIGATOR lat: 30.58333 lon: 114.26667 hasResults: False
nctId: NCT06288347 id: 216099 briefTitle: Study of the Efficacy of GGON: a Cognitive Training App for Orthorexia Nervosa. overallStatus: NOT_YET_RECRUITING date: 2024-05-02 date: 2024-06-17 date: 2024-06-17 date: 2024-03-01 date: 2024-03-15 name: University of Valencia class: OTHER briefSummary: The aim of the present study is to evaluate the efficacy of GGON to decrease the maladaptive beliefs associated with orthorexia nervosa (ON) in non-clinical adult population. Specifically, a randomized controlled trial with crossover assignment design and two groups (experimental and control) will be carried out in adults aged 18-65 years to assess the changes pre and post use the app. It's expected that after the use of the GGON app for 15 days are, at the primary level: decrease in the degree of ascription to dysfunctional beliefs associated with ON; and at the secondary level: decrease in orthorexia nervosa symptomatology, in eating symptomatology and in obsessive beliefs; increase in self-esteem; and no changes in drepessive symptomatology. These results are also expected to be maintained in subsequent follow-ups, at 15 days and a month after to finish the app in experimental group, and 15 days after to finish the app in control group. conditions: Orthorexia Nervosa studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: All participants were requested to complete web-based assessment, with questionnaires relating to maladaptive beliefs associated with ON, ortorexia, eating and depressive symptomatology, obsessive belifs and self-esteem at baseline (T1).